Table . Demography and Baseline Characteristics by Modal Dose of Perampanel and < 18y Age Group - All Treated Subjects with Partial Seizures (Safety Analysis Set) a: Subjects treated with placebo during the double-blind study. b: Subjects treated with perampanel in any study. Dose is the modal dose received. c: Not collected in all studies. Table . Subject Disposition and Primary Reason for Discontinuation by Last Daily Dose of Perampanel and <18y Age Group - All Treated Subjects with Partial Seizures (Safety Analysis Set) This table is based on the subject last disposition status under the treatment group a: Subjects treated with placebo during the double-blind study. b: Subjects treated with perampanel in any study. Dose is the last daily dose received. c: Discontinuation means discontinuation from the therapy (from the study). d: Corresponding adverse event(s) leading to withdrawal from the study / study drug were reported on the Adverse Event CRF. Table . Overview of Adverse Events - Double-blind Adjunctive Therapy Phase III Studies in Adolescents (< 18 years old) with Refractory Partial Seizures Safety Analysis Set A TEAE is defined as an adverse event that either begins on or after the first dose date and up to 30 days after the last dose date of study drug; or begins before the first dose date and increases in severity during the treatment period.For each row category, a subject with two or more adverse events in that category is counted only once. a: Subjects treated during the double-blind study. Dose groups are based on the actual treatment groups. Table . AEs by Decreasing Frequency - Double-blind Adjunctive Therapy Phase III Studies in Adolescents (< 18 years old) with Refractory Partial Seizures Safety Analysis Set. Table continued across two pages. A TEAE is defined as an adverse that either begins on or after the first dose date and up to 30 days after the last dose date of study drug; or begins before the first dose date and increases in severity during the treatment period. Subject with two or more adverse events with the same preferred term is counted only once for that preferred term. a: Subjects treated during the double-blind study. Dose groups are based on the actual treatment groups. b: MedDRA preferred terms are sorted in descending order of frequency in the total perampanel column.
Table . Demography and Baseline Characteristics by Modal Dose of Perampanel and < 18y Age Group - All Treated Subjects with Partial Seizures (Safety Analysis Set) a: Subjects treated with placebo during the double-blind study. b: Subjects treated with perampanel in any study. Dose is the modal dose received. c: Not collected in all studies. Table . Subject Disposition and Primary Reason for Discontinuation by Last Daily Dose of Perampanel and <18y Age Group - All Treated Subjects with Partial Seizures (Safety Analysis Set) This table is based on the subject last disposition status under the treatment group a: Subjects treated with placebo during the double-blind study. b: Subjects treated with perampanel in any study. Dose is the last daily dose received. c: Discontinuation means discontinuation from the therapy (from the study). d: Corresponding adverse event(s) leading to withdrawal from the study / study drug were reported on the Adverse Event CRF. Table . Overview of Adverse Events - Double-blind Adjunctive Therapy Phase III Studies in Adolescents (< 18 years old) with Refractory Partial Seizures Safety Analysis Set A TEAE is defined as an adverse event that either begins on or after the first dose date and up to 30 days after the last dose date of study drug; or begins before the first dose date and increases in severity during the treatment period.For each row category, a subject with two or more adverse events in that category is counted only once. a: Subjects treated during the double-blind study. Dose groups are based on the actual treatment groups. Table . AEs by Decreasing Frequency - Double-blind Adjunctive Therapy Phase III Studies in Adolescents (< 18 years old) with Refractory Partial Seizures Safety Analysis Set. Table continued across two pages. A TEAE is defined as an adverse that either begins on or after the first dose date and up to 30 days after the last dose date of study drug; or begins before the first dose date and increases in severity during the treatment period. Subject with two or more adverse events with the same preferred term is counted only once for that preferred term. a: Subjects treated during the double-blind study. Dose groups are based on the actual treatment groups. b: MedDRA preferred terms are sorted in descending order of frequency in the total perampanel column.